CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction Association of Cardiovascular Disease With Respiratory Disease Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry Heart Failure and Atrial Fibrillation, Like Fire and Fury Heart Failure With Improved Ejection Fraction-Is it Possible to Escape One’s Past? Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors Dilated cardiomyopathy: so many cardiomyopathies! A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF) The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure

Clinical Trial2018 Apr 12;378(15):1386-1395.

JOURNAL:N Engl J Med. Article Link

Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure

Mehra MR, Goldstein DJ, MOMENTUM 3 Investigators. Keywords: Magnetically Levitated Left Ventricular Assist Device; heart failure; pump thrombosis;

FULL TEXT PDF